Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Own bone marrow cells aimed at restarting ovaries

NCT ID NCT06302543

Cure Sponsor: abdulmajeed hammadi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether injecting a woman's own bone marrow cells into her ovaries can restore ovarian function in premature ovarian insufficiency, a condition where the ovaries stop working before age 40. Ten women with the diagnosis will receive the treatment, which involves collecting bone marrow under general anesthesia, concentrating the cells, and injecting them into the ovaries through the vagina under ultrasound guidance. The study will track changes in hormone levels and look for signs of egg follicle development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous bone marrow mononuclear cells injected into the ovaries
What this could lead to
If it works, this could offer women with premature ovarian insufficiency a way to restore ovarian function using their own cells, without donor eggs.
What could go wrong
This is a very small, single-arm study with no control group, so any changes seen may not be caused by the treatment. Bone marrow aspiration and ovarian injection carry risks such as bleeding, infection, and discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Mar 2024

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. clinical diagnosis of premature Ovarian insufficiency. 2. ineffective hormonal therapy. 3. biochemical evidence of high gonadotropins. Exclusion criteria: 1. solid or hematological malignancies. 2. bleeding disorders. 3. rejection of the procedure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature ovarian insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Premature ovarian insufficiency

Contacts and locations

Locations

  • Ministry of Health

    Baghdad, Iraq, 964, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.